Abstract #3952

Androgen receptor signaling in castration resistant prostate cancer tumor alters real-time lactate flux and lactate levels in vivo

Niki Zacharias^1,2, Jaehyuk Lee³, Sumankalai Ramachandran⁴, Sriram Shanmugavelandy³, James McHenry ³, Sankar Maity ⁴, Mark Titus ⁴, and Pratip Bhattacharya³

¹Urology, University of Texas MD Anderson Cancer Center, Houston, TX, United States, ²Bioengineering, Rice University, Houston, TX, United States, ³Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, United States, ⁴Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States

Non-invasive imaging of castration resistant prostate cancer (CRPC) subtypes remains a challenge in the clinic. CRPC can be subdivided grossly into two phenotypes 1) a morphologically small cell, chemosensitive, and androgen receptor (AR) negative subtype and 2) AR-dependent CRPC characterized by dysregulation of AR signaling. Employing hyperpolarized pyruvate conversion to lactate in vivo as well as lactate measurements ex vivo, we determined the difference in glycolysis between patient derived xenograft (PDX) animal models of these two CRPC subtypes. We have found increased pyruvate to lactate conversion (P <0.04) and higher lactate levels in AR-dependent compared to AR negative PDX models.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.